1. The use of at least one compound representing an amino acid sequence selected from the group consisting of SEFKHG (C), TLHEFRH (C), ILFRHG (C), TSVFRH (C), SQFRHY (C), LMFRHN (C ), SPNQFRH (C), ELFKHHL (C), THTDFRH (C), DEHPFRH (C), QSEFKHW (C), ADHDFRH (C), YEFRHAQ (C) and TEFRHKA (C), for the manufacture of a prophylactic drug and / or treatment of β-amyloidosis. ! 2. The use according to claim 1, wherein the compound is a polypeptide containing from 4 to 20 amino acid residues. ! 3. The use according to claim 1, wherein the compound is associated with a pharmaceutically acceptable carrier, preferably fissurella hemocyanin. ! 4. The use according to claim 1, wherein the compound is produced in pharmaceutical form for intravenous, subcutaneous, intradermal or intramuscular administration. ! 5. The use according to claim 1, wherein the compound is produced in pharmaceutical form together with an adjuvant, preferably aluminum hydroxide. ! 6. The use according to claim 1, wherein the compound is contained in the drug in an amount of from 0.1 ng to 10 mg, preferably from 10 ng to 1 mg, in particular from 100 ng to 10 μg. ! 7. The use according to claim 1, wherein the compound is used to treat and / or reduce the symptoms of synucleopathy. ! 8. The use according to claim 7, wherein the synucleopathy is selected from the group comprising Parkinson's disease, dementia with Levy bodies, multiple systemic atrophy and neurodegeneration with an accumulation of iron in the brain. ! 9. Use of at least one compound containing an amino acid sequence! ! where X1 is isoleucine (I) or valine (V),! X2 - tryptophan (W) or tyrosine (Y),! X3 - threonine (T), valine (V), alanine (A), methionine (M), glutamine (Q) or glycine (G),! X4 - proline (P), alanine (1. Применение, по меньшей мере, одного соединения, представляющего собой аминокислотную последовательность, которую выбирают из группы, включающей SEFKHG (C), TLHEFRH (C), ILFRHG (C), TSVFRH (C), SQFRHY (C), LMFRHN (C), SPNQFRH (C),
